-
Je něco špatně v tomto záznamu ?
Alcoholic liver disease
Brůha R., Dvořák K., Douša M., Petrtýl J., Švestka T.
Jazyk angličtina Země Česko
Typ dokumentu přehledy
Grantová podpora
NR9406
MZ0
CEP - Centrální evidence projektů
- MeSH
- alkoholická cirhóza jater diagnóza farmakoterapie terapie MeSH
- alkoholická steatóza jater diagnóza etiologie prevence a kontrola MeSH
- alkoholické nemoci jater epidemiologie etiologie patofyziologie MeSH
- alkoholismus komplikace metabolismus terapie MeSH
- analýza přežití MeSH
- ascites etiologie komplikace MeSH
- ezofageální a žaludeční varixy etiologie komplikace MeSH
- fibróza diagnóza etiologie patofyziologie MeSH
- financování organizované MeSH
- jaterní encefalopatie etiologie komplikace MeSH
- lidé MeSH
- portální hypertenze etiologie komplikace MeSH
- prognóza MeSH
- transplantace jater metody využití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Chronic intake of large quantities of alcohol causes damage to many organs, the liver being the most often affected one. In advanced countries, mortality due to liver diseases is directly proportional to alcohol consumption. 30 g of pure alcohol per day is regarded as a “safe” dose. Alcoholic liver disease may take the form of chronic illness (steatosis, steato-hepatitis, fibrosis and cirrhosis) or acute involvement (alcoholic hepatitis). Whereas steatosis is a relatively benign illness, the presence of cirrhosis of the liver means major life expectancy shortening. The actual stage of cirrhosis depends on the presence of complications – portal hypertension with bleeding oesophageal varices, ascites or hepatic encephalopathy. The median survival time of patients with advanced cirrhosis is 1–2 years. Serious alcoholic hepatitis has a mortality record of up to 50%. Absolute abstinence is a sine qua non condition for any treatment of alcoholic liver disease, the other therapeutic procedure are of a supportive nature and questionable significance. Corticoids can be used in the management of serious alcoholic hepatitis. Treatment in the stage of liver cirrhosis is similar to that in cirrhosis of any other aetiology. Cirrhotic patients who demonstrably abstain can be considered for transplantation leading to a markedly prolonged life expectancy.
Lit.: 39
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09004691
- 003
- CZ-PrNML
- 005
- 20140410105455.0
- 008
- 110214s2009 xr e eng||
- 009
- AR
- 035 __
- $a (PubMed)19655694
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Brůha, Radan, $d 1964- $7 xx0031692
- 245 10
- $a Alcoholic liver disease / $c Brůha R., Dvořák K., Douša M., Petrtýl J., Švestka T.
- 314 __
- $a Charles University, First Faculty of Medicine, 4th Department of Internal Medicine, Prague
- 504 __
- $a Lit.: 39
- 520 9_
- $a Chronic intake of large quantities of alcohol causes damage to many organs, the liver being the most often affected one. In advanced countries, mortality due to liver diseases is directly proportional to alcohol consumption. 30 g of pure alcohol per day is regarded as a “safe” dose. Alcoholic liver disease may take the form of chronic illness (steatosis, steato-hepatitis, fibrosis and cirrhosis) or acute involvement (alcoholic hepatitis). Whereas steatosis is a relatively benign illness, the presence of cirrhosis of the liver means major life expectancy shortening. The actual stage of cirrhosis depends on the presence of complications – portal hypertension with bleeding oesophageal varices, ascites or hepatic encephalopathy. The median survival time of patients with advanced cirrhosis is 1–2 years. Serious alcoholic hepatitis has a mortality record of up to 50%. Absolute abstinence is a sine qua non condition for any treatment of alcoholic liver disease, the other therapeutic procedure are of a supportive nature and questionable significance. Corticoids can be used in the management of serious alcoholic hepatitis. Treatment in the stage of liver cirrhosis is similar to that in cirrhosis of any other aetiology. Cirrhotic patients who demonstrably abstain can be considered for transplantation leading to a markedly prolonged life expectancy.
- 650 _2
- $a alkoholické nemoci jater $x epidemiologie $x etiologie $x patofyziologie $7 D008108
- 650 _2
- $a alkoholická cirhóza jater $x diagnóza $x farmakoterapie $x terapie $7 D008104
- 650 _2
- $a alkoholická steatóza jater $x diagnóza $x etiologie $x prevence a kontrola $7 D005235
- 650 _2
- $a fibróza $x diagnóza $x etiologie $x patofyziologie $7 D005355
- 650 _2
- $a alkoholismus $x komplikace $x metabolismus $x terapie $7 D000437
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a portální hypertenze $x etiologie $x komplikace $7 D006975
- 650 _2
- $a ezofageální a žaludeční varixy $x etiologie $x komplikace $7 D004932
- 650 _2
- $a jaterní encefalopatie $x etiologie $x komplikace $7 D006501
- 650 _2
- $a ascites $x etiologie $x komplikace $7 D001201
- 650 _2
- $a transplantace jater $x metody $x využití $7 D016031
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dvořák, Karel, $d 1980- $7 xx0134624
- 700 1_
- $a Douša, Miroslav $7 xx0076388
- 700 1_
- $a Petrtýl, Jaromír, $7 xx0089233 $d 1958-
- 700 1_
- $a Švestka, Tomislav $7 nlk20010094488
- 773 0_
- $w MED00013414 $t Prague medical report $g Roč. 110, č. 3 (2009), s. 181-190 $x 1214-6994
- 856 41
- $u http://pmr.cuni.cz/Data/Files/PragueMedicalReport/pmr_110_2009_03/pmr2009a0020.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 7 $c 1071 $y 7 $z 0
- 990 __
- $a 20091204095238 $b ABA008
- 991 __
- $a 20140410105545 $b ABA008
- 999 __
- $a ok $b bmc $g 700508 $s 562924
- BAS __
- $a 3
- BMC __
- $a 2009 $b 110 $c 3 $d 181-190 $i 1214-6994 $m Prague Medical Report $x MED00013414
- GRA __
- $a NR9406 $p MZ0
- LZP __
- $a 2009-56/ipal